Connect with us

Technology

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Published

on

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas.Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD, and double-digit royalties on annual salesAdditionally, Takeda will purchase a minority interest in Ascentage Pharma

ROCKVILLE, Md. and SUZHOU, China, June 14, 2024 /PRNewswire/ — Ascentage Pharma (6855 HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of among others, mainland China, Hong Kong, Macau, Taiwan, China.

Despite the impact TKIs have had in the treatment of patients with CML, there remains a significant unmet need for patients whose disease is resistant to these therapies or who develop hard-to-treat mutations following these treatments.

Under the terms of this option agreement, Ascentage Pharma is set to receive 100 million USD from Takeda to acquire the option to license olverembatinib. Ascentage will also be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD. Additionally, Ascentage Pharma is expected to receive a minority equity investment from Takeda.

As part of the agreement, Ascentage Pharma will continue to be solely responsible for all clinical development of olverembatinib before the potential exercise of the option to license olverembatinib. Olverembatinib is currently approved and marketed in China for the treatment of adult patients with TKI-resistant chronic-phase CML (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation, and in adult patients with CP-CML resistant to and/or intolerant of first-and second-generation TKIs.

“We are thrilled to enter into this agreement with Takeda, which would allow us to leverage the global commercial expertise of an organization with a proven track record and global oncology footprint to potentially broaden the impact olverembatinib could have on patients in need around the world,” said Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma. “Olverembatinib has already had a significant impact for patients with CML in China. We are excited to further the development of olverembatinib in our ongoing global registrational Phase 3 studies.”

“Throughout our history in oncology, Takeda has demonstrated a strong track record of working with companies that share our vision of bringing medicines to patients around the world with the highest unmet needs,” said Teresa Bitetti, president of Takeda’s Global Oncology Business Unit. “Through this agreement with Ascentage Pharma, we believe there is great potential to continue to advance this mission. We are highly encouraged by the promising results olverembatinib has shown in the clinic to date, and excited to have the opportunity to further develop and deliver it to patients with chronic myeloid leukemia and other hematological cancers.”

About Olverembatinib

Olverembatinib, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug has been included in the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates.

Investors Contacts:IR@ascentage.com
Media Contacts:PR@ ascentage.com

Forward-Looking Statements

The forward-looking statements in this article relate only to the events or information as of the date on which the statements are made. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ascentage-pharma-signs-option-agreement-with-takeda-to-enter-into-exclusive-global-license-for-olverembatinib-a-third-generation-bcr-abl-tyrosine-kinase-inhibitor-tki-302173047.html

SOURCE Ascentage Pharma

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

DATAMARK Technologies Welcomes Industry Veteran Deb Rozeboom to Client Success Team

Published

on

By

Ms. Rozeboom to strengthen client relationships and enhance satisfaction in new role as Client Success Manager

PITTSBURGH, May 19, 2025 /PRNewswire/ — DATAMARK Technologies, a leader in interoperable solutions for public safety location services, today announced that Deb Rozeboom has joined the organization as Client Success Manager. In her new role, Ms. Rozeboom will build lasting relationships with clients, enhance client satisfaction and ensure they derive maximum value from DATAMARK Technologies’ products and services.

Ms. Rozeboom’s efforts will ensure that clients stay at the forefront of public safety geographic information systems (GIS) innovation by consistently delivering services and solutions that align with client objectives and enhance interoperability and effectiveness. This commitment supports the transition to Next Generation 9-1-1 (NG9-1-1) and indoor mapping. At DATAMARK Technologies, Client Success Managers partner with clients to maximize their investments while continually advancing their capabilities.

“DATAMARK Technologies is dedicated to client success and enhancing public safety location services through excellence and advocacy,” said Robert Murphy, Chief Revenue Officer at DATAMARK Technologies. “Deb’s extensive experience in public safety GIS and expertise in NG9-1-1 will be invaluable as we continue to elevate the client experience.”

Ms. Rozeboom joins DATAMARK Technologies with over 20 years of experience managing complex NG9-1-1 projects nationwide. Prior to joining DATAMARK Technologies, she held various roles at GeoComm, including Product Manager, GIS Solutions Engineer and General Manager. Additionally, she has served as an Adjunct Instructor for the National Emergency Numbers Association (NENA), teaching several NG9-1-1 and Addressing courses. She also co-chairs the NENA NG9-1-1 GIS Data Model Standard workgroup and is a member of the Geospatial Professional Network (GPN) Location, Enterprise Addressing and Public Safety (LEAP) Committee.

Ms. Rozeboom holds a Bachelor of Science degree in Ecology and Field Biology, as well as a Master’s Certificate in GIS, from St. Cloud University. She also has several industry certifications, including NENA Emergency Number Professional (ENP), GISC Geographic Information Systems Professional (GISP) and PMI Project Management Professional (PMP).

About DATAMARK Technologies
DATAMARK Technologies provides a new era of 9-1-1 and redefines interoperability for the public safety industry. The company combines DATAMARK, Michael Baker International’s public safety division known for best-in-class geographic information systems (GIS) data management and software solutions, with Digital Data Technologies, LLC (DDT), a top-tier Next Generation 9-1-1 (NG9-1-1) location services provider.

This strategic union heralds a new era of 9-1-1 and redefines geospatial data management for the public safety industry. DATAMARK Technologies offers a fully integrated solution that empowers public safety agencies to manage, maintain and leverage GIS data to the highest industry standards. The unified approach breaks down barriers of data silos to improve call routing accuracy, offer seamless discrepancy resolution and provide unwavering location fidelity for call takers with enhanced interoperability.

Contact: Julia Covelli
julia.covelli@mbakerintl.com 
(866) 293-4609

View original content to download multimedia:https://www.prnewswire.com/news-releases/datamark-technologies-welcomes-industry-veteran-deb-rozeboom-to-client-success-team-302459122.html

SOURCE DATAMARK Technologies

Continue Reading

Technology

Coupa Research Shows CFOs Embrace AI as Antidote to Economic Volatility and Growth Enabler

Published

on

By

Third annual Strategic CFO Study finds 40% of CFOs rank AI as top growth investment area; 90% look to mastering spend management as key to success in tumultuous times

FOSTER CITY, Calif., May 19, 2025 /PRNewswire/ — Amidst global economic uncertainty, rising inflation, and volatile trade, AI investment ranked as the top strategy for growth across all global CFOs surveyed by Coupa – a potential panacea to the volatility they are facing.

The Strategic CFO Report: Turning Global Market Uncertainty into Opportunity, released today by Coupa, the leading AI-native total spend management platform, reveals that almost half (46%) of CFOs see prominent external threats – geopolitics and supply chain disruption – as the greatest risk to business, dampening optimism from the start of 2025. Most notably, the introduction of new tariffs has created an additional challenge for 42% of CFOs, with more than a quarter (28%) of US CFOs planning to or already increasing inventory levels in preparation.

“Today’s finance leaders are facing an alarming set of external pressures and are navigating an ever changing set of risks which challenges their decision making. Despite these dynamic forces, they are driving cost discipline in order to fuel growth, building more resilient supply chains, and scaling their use of AI to fuel more efficient organizations,” said Michael Agresta, Coupa’s CFO. “A unified spend management platform and strategy is proving to be mission-critical in these times to create the agility, visibility, and resilience leaders need to fuel sustainable growth. Coupa’s AI-driven total spend management platform is uniquely built to help our customers navigate uncertainty, and offers CFOs the cloud and AI-native tools to drive margin improvements in any economic environment, making it a critical component for a strategic CFO’s tech stack.”

Tariffs Spur Margin Erosion Concerns
With 69% of CFOs concerned about meeting year-end goals, and 40% reporting extreme concern, it’s clear that much of the financial optimism at the start of the year has dissipated. Most recently, new tariffs and the fear of global trade wars have driven CFOs to act urgently – including increasing inventory levels (22%), automating processes to reduce operating expenses (21%), engaging in hedging strategies (19%), increasing product pricing (19%), and restructuring supply chain (18%). When surveyed on the greatest external threats to business, U.S. CFOs reported slightly lower concern levels (40%) on tariffs compared to their European counterparts, with German CFOs (48%) indicating the highest concern of all countries surveyed.

CFOs Looking to AI to Fuel Growth and Confidence
Despite the uncertain state of the economy, CFOs are asking themselves how best to respond. For today’s finance leaders, this means not over-reacting to every market fluctuation and instead providing thoughtful and inspired leadership – moving away from short-term fixes and prioritizing durable, sustainable growth strategies. A majority (74%) of CFOs are growing increasingly confident in AI, ranking it as the top growth investment area (40% of all CFOs) and AI implementation confidence concerns dropped 23% year-over-year.

“CFOs, including myself, are increasingly championing AI use within their organizations, but to do so effectively they must create a governance structure that is capable of quantifying the performance and financial benefits of AI. Nearly a quarter (23%) of CFOs we surveyed identified this as one of the major obstacles they will face in the next year,” said Agresta. “Beyond the numbers, CFOs need to strategically consider how to prioritize the deployment of new AI strategies and tools across their organizations to identify the highest value use cases but also need to empower employees to think AI first in order to get enterprise-wide adoption.” 

Drowning in Data, Struggling in Silos
In case the state of the economy and trade turmoil wasn’t challenging enough, risk management continues to increase organizational complexity, as 1 in 4 CFOs cited cybersecurity threats, data breaches, and fraud as the largest obstacle they will face this year. CFOs have immense amounts of data at their fingertips – but only 28% of CFOs can access their spend data within a single system and nearly half (41%) struggle to react quickly to cut costs as part of this roadblock. Some organizations are modernizing their data management, but few (33%) have unified processes to manage spend comprehensively. Nearly 1 in 5 CFOs cited outdated systems and data silos as the main hurdles to digital transformation, highlighting the need for increased modern tech adoption to effectively manage data and decrease risk.

Read the full Coupa Clarity Report, The Strategic CFO: Turning Global Market Uncertainty into Opportunity here.

To learn more about Coupa’s leading total spend management platform can help during these turbulent times, visit coupa.com.

Methodology
Coupa Clarity reports provide unique data and insights to help business leaders make smarter decisions to fuel growth, drive efficiency and productivity, and improve performance. This survey was conducted among 500 CFOs and finance leaders across the US, UK, Ireland, France and Germany. The survey was carried out online with an email invitation between November and December 2024 by Wakefield Research on behalf of Coupa.

About Coupa
Coupa is the leader in AI-native total spend management. Using its trusted, community-generated, $8 trillion dataset, Coupa brings autonomous AI agents, a network of 10M+ buyers and suppliers, and leading apps together on one unified platform to seamlessly automate the buying process and connect to customers in a whole new way. With Coupa, you’ll make margins multiply™. Learn more at coupa.com and follow us on LinkedIn and X (Twitter).

View original content to download multimedia:https://www.prnewswire.com/news-releases/coupa-research-shows-cfos-embrace-ai-as-antidote-to-economic-volatility-and-growth-enabler-302458134.html

SOURCE Coupa Software

Continue Reading

Technology

Caltech Announces Eight Recipients of the 2025 National Brown Investigator Award

Published

on

By

Each investigator, recognized for curiosity-driven research in chemistry or physics, will receive up to $2 million over five years.

PASADENA, Calif., May 19, 2025 /PRNewswire/ — The Brown Institute for Basic Sciences at Caltech today announced the 2025 class of Brown Investigators. The cohort, the second to be selected through the Brown Institute for Basic Sciences, comprises eight distinguished mid-career faculty working on fundamental challenges in the physical sciences, particularly those with potential long-term practical applications in chemistry and physics. Each investigator will receive up to $2 million over five years.

The Brown Institute for Basic Sciences at Caltech, established in 2023 through a $400-million gift to the Institute from entrepreneur, philanthropist, and alumnus Ross M. Brown (BS ’56, MS ’57), seeks to advance fundamental science discoveries with the potential to seed breakthroughs that benefit society—a goal it shares with Caltech.

“Mid-career faculty are at a time in their careers when they are poised and prepared to make profound contributions to their fields,” Brown says, “My continuing hope is that the resources provided by the Brown Investigator Awards will allow them to pursue riskier innovative ideas that extend beyond their existing research efforts and align with new or developing passions, especially during this time of funding uncertainty.”

The 2025 investigators are:

Dmitry Abanin, Professor of Physics, Princeton University, to develop a new theoretical and computational framework to describe the emergent properties of quantum materials and synthetic quantum systems away from thermal equilibrium.

László Kürti, Professor of Chemistry, Rice University, to invent chemical strategies for constructing stable neutral polynitrogen cages—molecules made entirely from nitrogen atoms that store extraordinary energy. These elusive structures remain intact under ambient conditions yet release energy on demand without combustion and decompose cleanly into hot nitrogen gas, offering a revolutionary platform for propulsion and energy storage.  

Mark Levin, Associate Professor of Chemistry, University of Chicago, to translate lessons learned from skeletal editing of aromatic compounds (stable chemicals with a flat ring structure) to reactions with aliphatic compounds (three-dimensional, more reactive chemicals), with the goal of providing access to unusual compounds that are inaccessible using traditional chemical synthesis. 

Brad Ramshaw, Associate Professor of Physics, Cornell University, to develop a new technique using ultrasound to probe the electronic states of atomically thin materials.

Cindy Regal, Professor of Physics, University of Colorado Boulder, and Baur-SPIE Chair at JILA, to demonstrate quantum entanglement—a connection between particles like photons or atoms that persists despite their physical distance—with objects of larger mass than have been entangled before.

Xavier Roy, Professor of Chemistry, Columbia University, to design and explore materials in which electrons face competing pathways for motion, giving rise to complex behaviors that, if controlled, could enable new kinds of quantum technologies.

Hailiang Wang, Professor of Chemistry, Yale University, to expand electrocatalysis to convert inorganic waste molecules, such as CO2 and NOx, into valuable and functional organic compounds containing multiple carbon–carbon and carbon–nitrogen bonds.

Joel Yuen-Zhou, Associate Professor of Chemistry and Biochemistry, UC San Diego, for theoretical and computational work to utilize the sensitivity of some chemical reactions to the spin of the electron in photoredox catalysis to make the reaction select one of two enantiomers (mirror-image forms of compounds).

Brown established the Investigator Awards in 2020 through the Brown Science Foundation in support of the belief that “scientific discovery is a driving force in the improvement of the human condition,” according to its news release from the Science Philanthropy Alliance, which helped guide Brown in realizing his philanthropic vision.

“We’re delighted to partner with Ross Brown and the members of the Scientific Advisory Board of the Brown Institute for Basic Sciences to identify and support outstanding investigators in fundamental chemistry and physics,” says Caltech Provost David A. Tirrell, Carl and Shirley Larson Provostial Chair and Ross McCollum-William H. Corcoran Professor of Chemistry and Chemical Engineering.

A total of 21 investigators were recognized in the first four years of the program, including eight in the 2024 class, the first cohort to be installed under the auspices of the Brown Institute for Basic Sciences at Caltech.

Previous awardees include MIT’s Nuh Gedik, who is developing a new kind of microscopy that images electrons photo-emitted from a surface while also measuring their energy and momentum; Kerri A. Pratt from the University of Michigan, for research to discover the chemical compounds and chemical mechanisms that define the composition of the Arctic’s atmosphere, which is warming faster than elsewhere on Earth; Andrea Young of UC Santa Barbara, who is using novel fabrication techniques to make new kinds of qubits, the quantum computing analog of classical bits, in two-dimensional materials; Columbia University’s Tanya Zelevinsky, who studies spectroscopy of cold molecules for fundamental physics; Princeton University’s Waseem Bakr, who works with ultracold quantum gases to realize scalable architectures for quantum computation, and Robert Knowles, whose research will explore a novel hypothesis for the evolution of homochirality—the presence in nature of only one of two mirror-image forms of biomolecules. Caltech’s David Hsieh, Donald A. Glaser Professor of Physics and executive officer for physics, was among two inaugural recipients of the award in 2020.

Brown Investigators from all cohorts are invited to an annual meeting that offers opportunities to share ideas. The second annual meeting was held at Caltech in February 2025.

To determine the new cohort, a select number of research universities from across the country were invited to nominate faculty members who had earned tenure within the last 10 years and who are doing innovative fundamental research in the physical sciences. Nominees were then evaluated by an independent scientific review board that recommended grant winners. In administering the program, Caltech refrains from nominating its own scientists for Brown Investigator Awards. In return, the Institute draws other funds from the Brown gift to support fundamental research in chemistry and physics.

View original content:https://www.prnewswire.com/news-releases/caltech-announces-eight-recipients-of-the-2025-national-brown-investigator-award-302457427.html

SOURCE Caltech

Continue Reading

Trending